Bristol-Myers Squibb (BMY) reported Q2 non-GAAP earnings Thursday of $1.46 per diluted share, down from $2.07 a year earlier.
Analysts polled by FactSet expected $1.07.
Revenue for the quarter ended June 30 was $12.27 billion, up from $12.20 billion a year earlier.
Analysts surveyed by FactSet expected $11.39 billion.
The company lowered its full-year 2025 non-GAAP EPS guidance to a range of $6.35 to $6.65 from the previous range of $6.70 to $7.00. Analysts surveyed by FactSet expect $6.24.
The company increased its full-year 2025 revenue guidance to a range of $46.50 billion to $47.50 billion from prior outlook of $45.80 billion to $46.80 billion. Analysts polled by FactSet expect $46.28 billion.
The company's shares were up 2.8% in recent Thursday premarket activity.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.